ONCOSEC MEDICAL Inc: Nasdaq/NYSE listing notice — OncoSec receives Nasdaq minimum bid price deficiency notice; has until Nov 28, 2023 to regain compliance

ONCOSEC MEDICAL Inc

Received Nasdaq notice on June 1, 2023; bid price below $1.00 for 30 consecutive business days.
Has 180 calendar days (until November 28, 2023) to regain compliance by closing at $1.00+ for 10 consecutive days.
If not cured, may be eligible for additional 180-day grace period if it meets market value and other initial listing standards.
Company may consider options including reverse stock split to address noncompliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ONCOSEC MEDICAL Inc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

June 1, 2023, OncoSec Medical Incorporated (the “Company”) received notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days. The Notice has no immediate effect on the listing of the Company’s common stock, which will continue to trade at this time on the Nasdaq Capital Market under the symbol “ONCS.” In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001493152-23-020002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.